386 related articles for article (PubMed ID: 22453067)
1. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Wu CL; Ping SY; Yu CP; Yu DS
Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Ping SY; Wu CL; Yu DS
Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
Takeuchi A; Eto M; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Itsumi M; Naito S
Int J Oncol; 2012 May; 40(5):1691-6. PubMed ID: 22344606
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice.
Gu Y; Zhao W; Meng F; Qu B; Zhu X; Sun Y; Shu Y; Xu Q
Clin Immunol; 2010 Apr; 135(1):55-62. PubMed ID: 20015695
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.
Suddek GM
Cancer Chemother Pharmacol; 2011 May; 67(5):1035-44. PubMed ID: 20652569
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
Yeramian A; Sorolla A; Velasco A; Santacana M; Dolcet X; Valls J; Abal L; Moreno S; Egido R; Casanova JM; Puig S; Vilella R; Llombart-Cussac A; Matias-Guiu X; Martí RM
Int J Cancer; 2012 Feb; 130(4):967-78. PubMed ID: 21445974
[TBL] [Abstract][Full Text] [Related]
9. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model.
Chan ES; Patel AR; Hansel DE; Larchian WA; Heston WD
Urology; 2012 Sep; 80(3):736.e1-5. PubMed ID: 22676953
[TBL] [Abstract][Full Text] [Related]
11. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
Tsai YC; Yeh CH; Tzen KY; Ho PY; Tuan TF; Pu YS; Cheng AL; Cheng JC
Eur J Cancer; 2013 Apr; 49(6):1458-66. PubMed ID: 23153706
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.
Yashiro M; Shinto O; Nakamura K; Tendo M; Matsuoka T; Matsuzaki T; Kaizaki R; Miwa A; Hirakawa K
Int J Cancer; 2010 Feb; 126(4):1004-16. PubMed ID: 19621385
[TBL] [Abstract][Full Text] [Related]
14. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
17. Effects of sunitinib malate on growth of human bladder transitional cell line T24 in vitro.
Wen J; Li HZ; Ji ZG; Jin J
Chin Med Sci J; 2015 Mar; 30(1):51-5. PubMed ID: 25837361
[TBL] [Abstract][Full Text] [Related]
18. The Apoptosis Mechanism of Epirubicin Combined with BCG on Human Bladder Cancer Cells.
Luo Y; Fu X; Han B; Zhang F; Yuan L; Men H; Zhang S; Tian S; Dong B; Meng M
Anticancer Agents Med Chem; 2020; 20(13):1571-1581. PubMed ID: 32357825
[TBL] [Abstract][Full Text] [Related]
19. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-κB Signaling Pathways.
Korashy HM; Maayah ZH; Al Anazi FE; Alsaad AM; Alanazi IO; Belali OM; Al-Atawi FO; Alshamsan A
Anticancer Res; 2017 Sep; 37(9):4899-4909. PubMed ID: 28870911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
